Saturday, May 31, 2025

Latest

Mind Medicine Announces $10.0 Million Bought Deal At Large Discount To Share Price

Mind Medicine (NEO: MMED) this morning announced a bought deal financing with Eight Capital as sole bookrunner. The financing, for a total figure of $10.0 million, will be used to fund MindMed’s ongoing collaboration with that of University Hospital Basel’s Liechti Laboratory as well as for general corporate purposes.

The financing is being conducted at a price per unit of $0.53 which includes one subordinate voting share and one half warrant to purchase a subordinate voting share at a price of $0.79 for a period of 24 months following closing. The price is the offering is at a significant 13.1% discount to yesterdays closing price of $0.61 per share, and is nearly half the firms 52 week high of $0.99 set back in early March.

The bought deal, which has an over allotment option of 15%, can be expanded up to $11.5 million. The financing is expected to close on or before May 22, 2020.

Mind Medicine last traded at $0.61 on the Neo.


Information for this briefing was found via Sedar and Mind Medicine Inc. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

One Response

Leave a Reply

Video Articles

How To Profit From $3300 Gold? An Inside Look At A Massive 300,000 Oz Project | Martino De Ciccio

We’re At The Start of a Great Silver Boom | Ross McElroy & Andy Bowering – Apollo Silver Corp

Equinox Gold Q1 Earnings: When Everything Goes Wrong

Recommended

ESGold Begins Concentration Tests Ahead Of First Production

Sterling Metals Hits 0.21% Copper Over 482.8 Metres In First Drilling At Soo Copper project

Related News

MindMed Activist Investor Moves To Take Control Of Board

MindMed (NASDAQ: MNMD) has seen its activist investor file a preliminary proxy statement for its...

Friday, April 21, 2023, 09:41:30 AM

Psychedelics: The Eight Capital Primer

Eight Capital recently produced a primer on the psychedelic sector saying that the companies are...

Monday, June 14, 2021, 03:38:00 PM

Activist Investor Calls For MindMed CEO’s Termination Due To Alleged Fraudulent Acts

FCM MM Holdings, one of Mind Medicine’s (NEO: MMED) shareholders with a 6.1% stake, has...

Thursday, November 3, 2022, 03:10:00 PM

Mind Medicine: Canaccord Maintains Ratings Following Financial Results

On Friday, November 13th, Mind Medicine (NEO: MMED) reported their third quarter 2020 financial results....

Tuesday, November 17, 2020, 10:17:00 AM

Shroom Progress! MindMed Advances Towards a Phase 2 LSD Microdosing Trial For Adult ADHD

Aftermarket MindMed (NEO:MMED) announced they entered into a clinical trial agreement with Maastricht University to...

Monday, May 11, 2020, 10:29:04 PM